Recurrences of renal cell carcinoma (RCC) following curative surgery are uncommon among patients with low-risk compared with intermediate- or high-risk disease, researchers reported at the 2017 congress of the European Association of Urology in London. The percentage of potentially curable recurrences, however, is similar for all 3 risk groups.
Using the RECUR database, Saeed Dabestani, MD, of Lund University in Malmö, Sweden, and colleagues examined RCC recurrence patterns and management. The researchers assessed 1266 patients (mean age 65 years) who underwent surgery for localized RCC. After a median follow-up of 61.2 months, 252 patients (19.9%) experienced recurrence. In 119 cases (47.2%), the recurrence was potentially curable. Isolated local, solitary and oligometastatic (3 or fewer lesions at a single site) recurrences were considered curable by local therapeutic strategies.
The 5-year risk of recurrence for low- intermediate- and high-risk patients was 4.8%, 18.1%, and 46.3%, respectively, and the percentage of recurrences that were potentially curable was 51.6%, 50.7%, and 42.8%, respectively, Dr Dabestani’s group reported in a poster presentation. The median time to recurrence was 41.6, 25.5, and 14.3 months, respectively. The time to recurrence was 23.8 months for potentially curable recurrences compared with 17.7 months for incurable patients. Curative intent treatment for recurrence was offered to 34.1%, 30.1%, 16.7% of patients in the low-, intermediate-, and high-risk groups, according to the researchers.
“More effort should perhaps be put into detecting recurrence in the intermediate and high risk groups as they harbor more patients with recurrences that are potentially curable,” the investigators concluded.
1. Dabestani S, Beisland C, Gudmundsson E, et al. Non-metastatic renal cell carcinoma follow-up , recurrences and outcomes-a RECUR database analysis. Presented at the 2017 congress of the European Association of Urology in London. Poster 647.